Clinical Trial Update: ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD) [Phase 2]

View source ↗

Summary

Open-label extension Phase 2 trial of ML-004 in adults and adolescents with autism spectrum disorder is currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autism Spectrum Disorder

Drugs mentioned

• ML-004

Snippet

Sponsor: MapLight Therapeutics | Conditions: Autism Spectrum Disorder | Phase 2 | Status: ENROLLING_BY_INVITATION